KPTI

SEC source: 0001209191-20-011697 · doc4.xml · nonDerivative · entry 1

Shah Jatin · CIK 0001782186 · EVP, Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,759

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 19, 2020 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.

SEC source: 0001209191-20-011696 · doc4.xml · nonDerivative · entry 1

Frenkel Ran · CIK 0001623108 · Chief Dev Operations Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,066

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 19, 2020 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.

SEC source: 0001209191-20-011692 · doc4.xml · nonDerivative · entry 1

Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,367

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 19, 2020 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.

SEC source: 0001209191-20-011690 · doc4.xml · nonDerivative · entry 2

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 555,122

F3 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the spouse of the reporting person.

F4 · price: The sale price of the spouse of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 19, 2020 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.

SEC source: 0001209191-20-011690 · doc4.xml · nonDerivative · entry 1

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 756,489

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 19, 2020 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.

SEC source: 0001209191-20-010742 · doc4.xml · derivative · entry 4

Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 65,400

Underlying: Common Stock · 21,800 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.

F3 · derivative.exercise_date: On February 15, 2019, the spouse of the reporting person was granted 87,200 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2020. Vested shares will be delivered to the spouse of the reporting person as soon as practicable following the vesting date, but in any an event within 30 days of such date.

F3 · derivative.expiration_date: On February 15, 2019, the spouse of the reporting person was granted 87,200 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2020. Vested shares will be delivered to the spouse of the reporting person as soon as practicable following the vesting date, but in any an event within 30 days of such date.

SEC source: 0001209191-20-010742 · doc4.xml · derivative · entry 3

Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,400

Underlying: Common Stock · 21,800 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.

F2 · derivative.exercise_date: On February 15, 2019, the reporting person was granted 87,200 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2020. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any an event within 30 days of such date.

F2 · derivative.expiration_date: On February 15, 2019, the reporting person was granted 87,200 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2020. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any an event within 30 days of such date.

SEC source: 0001209191-20-010742 · doc4.xml · nonDerivative · entry 2

Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 765,306

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.

SEC source: 0001209191-20-010742 · doc4.xml · nonDerivative · entry 1

Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 563,939

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.

SEC source: 0001209191-20-010756 · doc4.xml · derivative · entry 2

Frenkel Ran · CIK 0001623108 · Chief Dev Operations Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,025

Underlying: Common Stock · 9,675 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.

F3 · derivative.exercise_date: On February 15, 2019, the reporting person was granted 38,700 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2020. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any an event within 30 days of such date.

F3 · derivative.expiration_date: On February 15, 2019, the reporting person was granted 38,700 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2020. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any an event within 30 days of such date.

SEC source: 0001209191-20-010756 · doc4.xml · nonDerivative · entry 1

Frenkel Ran · CIK 0001623108 · Chief Dev Operations Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,041

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.

F2 · balance_after: Includes 4,633 shares acquired under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan.

SEC source: 0001209191-20-010762 · doc4.xml · derivative · entry 2

Shah Jatin · CIK 0001782186 · EVP, Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,550

Underlying: Common Stock · 4,850 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.

F3 · derivative.exercise_date: On February 15, 2019, the reporting person was granted 19,400 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2020. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any an event within 30 days of such date.

F3 · derivative.expiration_date: On February 15, 2019, the reporting person was granted 19,400 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2020. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any an event within 30 days of such date.

SEC source: 0001209191-20-010762 · doc4.xml · nonDerivative · entry 1

Shah Jatin · CIK 0001782186 · EVP, Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,134

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.

F2 · balance_after: Includes 2,659 shares acquired under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan.

SEC source: 0001209191-20-010750 · doc4.xml · derivative · entry 2

Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,025

Underlying: Common Stock · 9,675 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.

F2 · derivative.exercise_date: On February 15, 2019, the reporting person was granted 38,700 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2020. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any an event within 30 days of such date.

F2 · derivative.expiration_date: On February 15, 2019, the reporting person was granted 38,700 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2020. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any an event within 30 days of such date.

SEC source: 0001209191-20-010750 · doc4.xml · nonDerivative · entry 1

Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,328

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.

SEC source: 0001209191-20-010747 · doc4.xml · derivative · entry 4

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 65,400

Underlying: Common Stock · 21,800 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.

F3 · derivative.exercise_date: On February 15, 2019, the spouse of the reporting person was granted 87,200 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2020. Vested shares will be delivered to the spouse of the reporting person as soon as practicable following the vesting date, but in any an event within 30 days of such date.

F3 · derivative.expiration_date: On February 15, 2019, the spouse of the reporting person was granted 87,200 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2020. Vested shares will be delivered to the spouse of the reporting person as soon as practicable following the vesting date, but in any an event within 30 days of such date.

SEC source: 0001209191-20-010747 · doc4.xml · derivative · entry 3

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,400

Underlying: Common Stock · 21,800 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.

F2 · derivative.exercise_date: On February 15, 2019, the reporting person was granted 87,200 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2020. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any an event within 30 days of such date.

F2 · derivative.expiration_date: On February 15, 2019, the reporting person was granted 87,200 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2020. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any an event within 30 days of such date.

SEC source: 0001209191-20-010747 · doc4.xml · nonDerivative · entry 2

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 563,939

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.

SEC source: 0001209191-20-010747 · doc4.xml · nonDerivative · entry 1

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 765,306

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.

SEC source: 0001209191-20-008727 · doc4.xml · derivative · entry 5

Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 376,061

Underlying: Common Stock · 10,000 shares

Expires 2023-09-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F5 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on September 3, 2014, and the remaining 75% vested in 36 equal monthly installments thereafter.

SEC source: 0001209191-20-008727 · doc4.xml · nonDerivative · entry 2

Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 542,139

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $17.215 to $17.85, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-20-008727 · doc4.xml · nonDerivative · entry 1

Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 552,139

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-20-008729 · doc4.xml · derivative · entry 6

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 376,061

Underlying: Common Stock · 10,000 shares

Expires 2023-09-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person.

F5 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on September 3, 2014, and the remaining 75% vested in 36 equal monthly installments thereafter.

SEC source: 0001209191-20-008729 · doc4.xml · nonDerivative · entry 4

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 542,139

F3 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person.

F4 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $17.215 to $17.85, inclusive. The spouse of the reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-20-008729 · doc4.xml · nonDerivative · entry 3

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 552,139

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person.

SEC source: 0001209191-20-008727 · doc4.xml · derivative · entry 6

Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 420,303

Underlying: Common Stock · 10,000 shares

Expires 2023-09-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person.

F5 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on September 3, 2014, and the remaining 75% vested in 36 equal monthly installments thereafter.

SEC source: 0001209191-20-008727 · doc4.xml · nonDerivative · entry 4

Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 743,506

F3 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person.

F4 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $16.793 to $17.21, inclusive. The spouse of the reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-20-008727 · doc4.xml · nonDerivative · entry 3

Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 753,506

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person.

SEC source: 0001209191-20-008729 · doc4.xml · derivative · entry 5

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 420,303

Underlying: Common Stock · 10,000 shares

Expires 2023-09-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F5 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on September 3, 2014, and the remaining 75% vested in 36 equal monthly installments thereafter.

SEC source: 0001209191-20-008729 · doc4.xml · nonDerivative · entry 2

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 743,506

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $16.793 to $17.21, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-20-008729 · doc4.xml · nonDerivative · entry 1

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 753,506

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-20-007515 · doc4.xml · derivative · entry 2

Lewis Tanya · CIK 0001451038 · EVP,Chief Reg.&Quality Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,600

Underlying: Common Stock · 22,600 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Karyopharm Therapeutics Inc. common stock.

F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 5, 2021, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date.

F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 5, 2021, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date.

SEC source: 0001209191-20-007515 · doc4.xml · derivative · entry 1

Lewis Tanya · CIK 0001451038 · EVP,Chief Reg.&Quality Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,600

Underlying: Common Stock · 60,600 shares

Expires 2030-02-04

F1 · derivative.exercise_date: This option was granted on February 5, 2020. The shares underlying this option vest as to 25% of the shares on February 5, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001209191-20-007483 · doc4.xml · derivative · entry 4

Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 57,200

Underlying: Common Stock · 57,200 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Karyopharm Therapeutics Inc. common stock.

F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 5, 2021, the first anniversary of the grant date. Vested shares will be delivered to the spouse of the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date.

F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 5, 2021, the first anniversary of the grant date. Vested shares will be delivered to the spouse of the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date.

SEC source: 0001209191-20-007483 · doc4.xml · derivative · entry 3

Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,200

Underlying: Common Stock · 57,200 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Karyopharm Therapeutics Inc. common stock.

F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 5, 2021, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date.

F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 5, 2021, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date.

SEC source: 0001209191-20-007483 · doc4.xml · derivative · entry 2

Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 153,500

Underlying: Common Stock · 153,500 shares

Expires 2030-02-04

F1 · derivative.exercise_date: This option was granted on February 5, 2020. The shares underlying this option vest as to 25% of the shares on February 5, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001209191-20-007483 · doc4.xml · derivative · entry 1

Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 153,500

Underlying: Common Stock · 153,500 shares

Expires 2030-02-04

F1 · derivative.exercise_date: This option was granted on February 5, 2020. The shares underlying this option vest as to 25% of the shares on February 5, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001209191-20-007514 · doc4.xml · derivative · entry 2

Shah Jatin · CIK 0001782186 · EVP, Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,600

Underlying: Common Stock · 22,600 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Karyopharm Therapeutics Inc. common stock.

F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 5, 2021, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date.

F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 5, 2021, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date.

SEC source: 0001209191-20-007514 · doc4.xml · derivative · entry 1

Shah Jatin · CIK 0001782186 · EVP, Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,600

Underlying: Common Stock · 60,600 shares

Expires 2030-02-04

F1 · derivative.exercise_date: This option was granted on February 5, 2020. The shares underlying this option vest as to 25% of the shares on February 5, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001209191-20-007510 · doc4.xml · derivative · entry 2

Frenkel Ran · CIK 0001623108 · Chief Dev Operations Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,600

Underlying: Common Stock · 22,600 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Karyopharm Therapeutics Inc. common stock.

F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 5, 2021, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date.

F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 5, 2021, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date.

SEC source: 0001209191-20-007510 · doc4.xml · derivative · entry 1

Frenkel Ran · CIK 0001623108 · Chief Dev Operations Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,600

Underlying: Common Stock · 60,600 shares

Expires 2030-02-04

F1 · derivative.exercise_date: This option was granted on February 5, 2020. The shares underlying this option vest as to 25% of the shares on February 5, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001209191-20-007502 · doc4.xml · derivative · entry 2

Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,300

Underlying: Common Stock · 30,300 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Karyopharm Therapeutics Inc. common stock.

F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 5, 2021, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date.

F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 5, 2021, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date.

SEC source: 0001209191-20-007502 · doc4.xml · derivative · entry 1

Primiano Christopher Brett · CIK 0001603510 · EVP, CBO, GC & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,200

Underlying: Common Stock · 81,200 shares

Expires 2030-02-04

F1 · derivative.exercise_date: This option was granted on February 5, 2020. The shares underlying this option vest as to 25% of the shares on February 5, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001209191-20-007508 · doc4.xml · derivative · entry 2

Mason Michael · CIK 0001514291 · SVP, CFO & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,600

Underlying: Common Stock · 32,600 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Karyopharm Therapeutics Inc. common stock.

F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 5, 2021, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date.

F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 5, 2021, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date.

SEC source: 0001209191-20-007508 · doc4.xml · derivative · entry 1

Mason Michael · CIK 0001514291 · SVP, CFO & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,600

Underlying: Common Stock · 87,600 shares

Expires 2030-02-04

F1 · derivative.exercise_date: This option was granted on February 5, 2020. The shares underlying this option vest as to 25% of the shares on February 5, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001209191-20-007496 · doc4.xml · derivative · entry 4

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 57,200

Underlying: Common Stock · 57,200 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Karyopharm Therapeutics Inc. common stock.

F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 5, 2021, the first anniversary of the grant date. Vested shares will be delivered to the spouse of the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date.

F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 5, 2021, the first anniversary of the grant date. Vested shares will be delivered to the spouse of the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date.

SEC source: 0001209191-20-007496 · doc4.xml · derivative · entry 3

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,200

Underlying: Common Stock · 57,200 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Karyopharm Therapeutics Inc. common stock.

F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 5, 2021, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date.

F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 5, 2021, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date.

SEC source: 0001209191-20-007496 · doc4.xml · derivative · entry 2

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 153,500

Underlying: Common Stock · 153,500 shares

Expires 2030-02-04

F1 · derivative.exercise_date: This option was granted on February 5, 2020. The shares underlying this option vest as to 25% of the shares on February 5, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001209191-20-007496 · doc4.xml · derivative · entry 1

Shacham Sharon · CIK 0001588438 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 153,500

Underlying: Common Stock · 153,500 shares

Expires 2030-02-04

F1 · derivative.exercise_date: This option was granted on February 5, 2020. The shares underlying this option vest as to 25% of the shares on February 5, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001209191-20-003088 · doc4.xml · derivative · entry 7

Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 386,061

Underlying: Common Stock · 10,000 shares

Expires 2023-09-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F9 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on September 3, 2014, and the remaining 75% vested in 36 equal monthly installments thereafter.